Your browser doesn't support javascript.
loading
Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation.
Saberian, Chantal; Abdel-Wahab, Noha; Abudayyeh, Ala; Rafei, Hind; Joseph, Jacinth; Rondon, Gabriela; Whited, Laura; Gruschkus, Stephen; Fa'ak, Faisal; Daher, May; Knape, Cristina; Safa, Houssein; Shoukier, Mahran; Suarez-Almazor, Maria E; Marcotulli, Megan; Ludford, Kaysia; Gulbis, Alison M; Konopleva, Marina; Ohanian, Maro; Ravandi, Farhad; Garcia-Manero, Guillermo; Oran, Betul; Popat, Uday R; Mehta, Rotesh; Alousi, Amin M; Daver, Naval; Champlin, Richard; Diab, Adi; Al-Atrash, Gheath.
Afiliação
  • Saberian C; Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Abdel-Wahab N; Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Abudayyeh A; Section of Rheumatology and Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Rafei H; Department of Rheumatology and Rehabilitation, Faculty of Medicine, Assiut University Hospitals, Assiut, Egypt.
  • Joseph J; Section of Nephrology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Rondon G; Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Whited L; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Gruschkus S; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Fa'ak F; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Daher M; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Knape C; Department of Internal Medicine, Piedmont Athens Regional Medical Center Athens, Athens, Georgia, USA.
  • Safa H; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Shoukier M; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Suarez-Almazor ME; Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Marcotulli M; Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Ludford K; Section of Rheumatology and Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Gulbis AM; Department of Health Service Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Konopleva M; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Ohanian M; Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Ravandi F; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Oran B; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Popat UR; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Mehta R; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Alousi AM; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Daver N; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Champlin R; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Diab A; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Al-Atrash G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
J Immunother Cancer ; 9(2)2021 02.
Article em En | MEDLINE | ID: mdl-33637601
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Leucemia Mieloide Aguda / Transplante de Células-Tronco Hematopoéticas / Ciclofosfamida / Inibidores de Checkpoint Imunológico / Doença Enxerto-Hospedeiro / Imunossupressores Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País como assunto: America do norte Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Leucemia Mieloide Aguda / Transplante de Células-Tronco Hematopoéticas / Ciclofosfamida / Inibidores de Checkpoint Imunológico / Doença Enxerto-Hospedeiro / Imunossupressores Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País como assunto: America do norte Idioma: En Ano de publicação: 2021 Tipo de documento: Article